<bill session="117" type="h" number="1829" updated="2023-01-11T13:48:18Z">
  <state datetime="2021-03-11">REFERRED</state>
  <status>
    <introduced datetime="2021-03-11"/>
  </status>
  <introduced datetime="2021-03-11"/>
  <titles>
    <title type="display">Pharmacy Benefit Manager Accountability Study Act of 2021</title>
    <title type="official" as="introduced">To require the Government Accountability Office to study the role pharmaceutical benefit managers play in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes.</title>
    <title type="short" as="introduced">Pharmacy Benefit Manager Accountability Study Act of 2021</title>
  </titles>
  <sponsor bioguide_id="H001086"/>
  <cosponsors>
    <cosponsor bioguide_id="A000378" joined="2021-06-17"/>
    <cosponsor bioguide_id="C001039" joined="2022-09-19"/>
    <cosponsor bioguide_id="C001054" joined="2021-03-16"/>
    <cosponsor bioguide_id="C001103" joined="2021-03-11"/>
    <cosponsor bioguide_id="C000266" joined="2021-10-25"/>
    <cosponsor bioguide_id="C001118" joined="2022-09-19"/>
    <cosponsor bioguide_id="C001068" joined="2021-11-01"/>
    <cosponsor bioguide_id="D000619" joined="2022-04-25"/>
    <cosponsor bioguide_id="G000568" joined="2021-03-19"/>
    <cosponsor bioguide_id="G000576" joined="2022-01-19"/>
    <cosponsor bioguide_id="G000591" joined="2021-06-28"/>
    <cosponsor bioguide_id="H001084" joined="2022-08-12"/>
    <cosponsor bioguide_id="K000395" joined="2021-03-18"/>
    <cosponsor bioguide_id="K000376" joined="2022-07-26"/>
    <cosponsor bioguide_id="M000194" joined="2022-12-07"/>
    <cosponsor bioguide_id="M000871" joined="2022-07-11"/>
    <cosponsor bioguide_id="M001211" joined="2022-04-21"/>
    <cosponsor bioguide_id="M001215" joined="2021-06-28"/>
    <cosponsor bioguide_id="M001210" joined="2021-06-28"/>
    <cosponsor bioguide_id="N000190" joined="2022-04-21"/>
    <cosponsor bioguide_id="O000086" joined="2022-06-13"/>
    <cosponsor bioguide_id="P000605" joined="2022-03-29"/>
    <cosponsor bioguide_id="P000616" joined="2022-05-16"/>
    <cosponsor bioguide_id="P000599" joined="2021-03-26"/>
    <cosponsor bioguide_id="R000103" joined="2021-10-25"/>
    <cosponsor bioguide_id="S000929" joined="2021-06-28"/>
    <cosponsor bioguide_id="T000467" joined="2022-02-01"/>
    <cosponsor bioguide_id="V000133" joined="2021-03-16"/>
    <cosponsor bioguide_id="W000800" joined="2021-06-22"/>
  </cosponsors>
  <actions>
    <action datetime="2021-03-11">
      <text>Introduced in House</text>
    </action>
    <action datetime="2021-03-11" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2021-03-12">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="s" number="298" relation="identical"/>
    <bill session="117" type="s" number="4293" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Congressional oversight"/>
    <term name="Drug therapy"/>
    <term name="Government employee pay, benefits, personnel management"/>
    <term name="Government studies and investigations"/>
    <term name="Health care costs and insurance"/>
    <term name="Inflation and prices"/>
    <term name="Medicaid"/>
    <term name="Medicare"/>
    <term name="Prescription drugs"/>
    <term name="Social Welfare"/>
  </subjects>
  <amendments/>
  <summary date="2021-05-28T19:50:01Z" status="Introduced in House">Pharmacy Benefit Manager Accountability Study Act of 2021

This bill requires the Government Accountability Office to report on the role of pharmacy benefit managers in the pharmaceutical supply chain and recommend legislative actions to lower the cost of prescription drugs. The report must address the use of rebates and fees, the average prior authorization approval time, and the use of step therapy within the 10 largest pharmacy benefit managers.</summary>
</bill>
